AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

Bristol-Myers Squibb (BMY) stock was upgraded by Leerink Partners based on a potential sales boost for its schizophrenia ...

After months of investor apathy, Bristol-Myers Squibb's business is finally starting to blossom. One of his most recent ...

Leerink upgrades Bristol-Myers Squibb with an increased price target and strong sales projections for Cobenfy and milvexian, ...

We’re maintaining our fair value estimate for AbbVie at $176 and slightly raising our fair value for Bristol-Myers Squibb to ... approved schizophrenia drug Cobenfy. However, both phase 2 ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

BMO Capital analyst Evan Seigerman raised the firm’s price target on Bristol Myers (BMY) to $61 from $57 and keeps a Market Perform ...

Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $39 from $36 and keeps an Underweight rating on the shares ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first-in-class muscarinic agonist, for the treatment of schizophrenia in adults.

Cobenfy, which comes in capsule form ... chief commercialization officer for Bristol Myers Squibb, which will distribute the drug. Psychiatrists anticipate the drug could help more people to ...